Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CDH1 | P12830 | 1/20 | 0.40 |
| ▸ | APC | P25054 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 3/20 | 0.40 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.40 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.40 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907363 | 0.90 | DOT1L (0.44) | MAPKAPK2CSNK2A2CSNK2BTSHRKMO | |
| SCHEMBL9907348 | 0.86 | MAPKAPK2 (0.44) | MAPKAPK2CSNK2A2CSNK2BCDH1APC | |
| SCHEMBL9907342 | 0.86 | SRD5A2 (0.49) | MAPKAPK2CSNK2A2CSNK2BCDH1APC | |
| SCHEMBL9907351 | 0.84 | HTR5A (0.42) | MAPKAPK2CSNK2A2CSNK2BTSHRKMO | |
| SCHEMBL9907381 | 0.84 | HTT (0.49) | CSNK2A2CSNK2BCNR1ALDH1A1L3MBTL1 | |
| SCHEMBL9907362 | 0.83 | MAPKAPK2 (0.49) | MAPKAPK2CSNK2A2CSNK2BTSHRCDH1 | |
| SCHEMBL9907809 | 0.82 | HTR5A (0.54) | — | |
| SCHEMBL9907344 | 0.82 | HTR5A (0.43) | MAPKAPK2CSNK2A2CSNK2BKMOTTR | |
| SCHEMBL7689552 | 0.82 | TSHR (0.48) | MAPKAPK2CSNK2A2CSNK2BTSHRCDH1 | |
| SCHEMBL9907462 | 0.81 | CSNK2A2 (0.43) | MAPKAPK2CSNK2A2CSNK2BIP6K1IP6K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| EP-2463276-B1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| EP-2463276-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | MAPKAPK2 4333/4885CSNK2A2 4132/4885CSNK2B 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.